Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Automated Versus Manual Oxygen Titration With the EMILY.AI Device in Hospitalized Patients With Acute Respiratory Failure

2026. november 9. frissítette: Aether Tech S.L.

Functional, Clinical, and Predictive Validation Study of the EMILY AI Device in Patients With Acute and Chronic Respiratory Failure: Randomized Substudy in a Conventional Hospital Ward

This randomized study evaluates EMILY.AI, an investigational (non-CE-marked) smart oxygen valve that automatically adjusts the oxygen flow delivered to a patient, second by second, according to oxygen saturation (SpO2), heart rate and respiratory rate measured by a pulse oximeter.

Adults admitted to the pulmonology ward of Hospital Universitario Fundación Jiménez Díaz (Madrid, Spain) with acute respiratory failure are randomly assigned to receive oxygen titrated automatically by EMILY.AI or oxygen managed as usual by the nursing team, from randomization until hospital discharge. All participants wear the device; in the usual-care group it only records data.

The study compares the time patients stay within their target saturation range, episodes of low and high oxygen, nursing workload, oxygen use, length of stay and patient experience. This substudy is part of clinical investigation FJD-EMILY-23-02, whose other substudies are registered in separate records.

A tanulmány áttekintése

Részletes leírás

Background On conventional hospital wards, oxygen is usually given at a fixed flow and saturation is checked about once per nursing shift, so periods of hypoxaemia or hyperoxaemia can go undetected. EMILY.AI combines a medical-grade oxygen valve with an edge-computing fuzzy-logic algorithm that sets the oxygen flow every second, with continuous logging of physiological signals and delivered flow.

Design Prospective, single-blind (participant), randomized, parallel-group study. Participants are randomized 1:1 to the EMILY arm (automatic titration) or the MANUAL arm (usual care with nursing monitoring every 8 hours and a fixed oxygen prescription), using permuted blocks of 4 stratified by main admission diagnosis (COPD exacerbation, pneumonia, interstitial lung disease, other) and prior long-term home oxygen therapy (yes or no). Allocation takes place after eligibility is confirmed and informed consent is signed.

Intervention and follow-up All participants are connected to the EMILY.AI device continuously from randomization until hospital discharge. In the EMILY arm the device titrates oxygen autonomously to keep SpO2 within the target range for the type of respiratory failure (hypoxaemic 91-97%; hypercapnic 91-94%). In the MANUAL arm the device works in fixed mode, recording SpO2, heart rate and respiratory rate without changing the flow, and nurses adjust oxygen as usual. Conventional back-up oxygen is available at all times.

Sample size 100 participants: 80 planned for the main comparison and approximately 20 added by protocol amendment (CIP v8.0) to further validate an adjustment of the algorithm parameter that sets the minimum oxygen flow in hypoxaemic patients. All 100 are randomized in the same way. As a pilot functional validation, no formal sample size calculation was performed.

The protocol FJD-EMILY-23-02 also includes a substudy in the Respiratory Intermediate Care Unit and an exercise substudy (six-minute walk test), registered separately.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

100

Fázis

  • Nem alkalmazható

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

  • Név: Alba Naya Prieto, MD
  • Telefonszám: +34 915 50 48 00
  • E-mail: alba.naya@fjd.es

Tanulmányozza a kapcsolattartók biztonsági mentését

  • Név: Sarah Beatrice Heili Frades, MD, PhD
  • Telefonszám: +34 915 50 48 00
  • E-mail: SHeili@fjd.es

Tanulmányi helyek

      • Madrid, Spanyolország, 28040
        • Hospital Universitario Fundación Jiménez Díaz
        • Kapcsolatba lépni:
          • Sarah Beatrice Heili Frades Zimmermann MD, PhD
          • Telefonszám: +34 915 50 48 00
          • E-mail: SHeili@fjd.es
        • Kapcsolatba lépni:
        • Kutatásvezető:
          • Sarah Beatrice Heili Frades Zimmermann, MD, PhD

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év és régebbi (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Men and women aged 18 years or older.
  • Admitted to the general pulmonology ward (Unit 67) of Hospital Universitario Fundación Jiménez Díaz.
  • Acute respiratory failure, defined as baseline arterial PaO2 below 60 mmHg or the need for supplemental oxygen to maintain SpO2 above 90%. Patients on long-term oxygen therapy are eligible if a clinical deterioration requires a higher-than-usual oxygen flow to maintain SpO2 above 90%.
  • Signed informed consent.

Exclusion Criteria:

  • Anatomical abnormalities preventing correct placement of the pulse oximeter.
  • Pregnancy or breastfeeding (women of childbearing potential require a negative pregnancy test at screening).
  • Need for non-invasive ventilation or high-flow nasal cannula at admission.
  • Palliative care or limitation of therapeutic effort at admission.
  • Expected hospital stay under 48 hours.
  • Clinical situations expected to determine length of stay independently of oxygen therapy, such as intravenous antibiotics for more than 10 days, scheduled interventional or surgical procedures, active social care needs that may delay discharge, a non-respiratory main admission diagnosis, or acute or decompensated non-respiratory comorbidities.
  • Known or suspected carbon monoxide poisoning or methemoglobinemia.
  • Severe hypercapnia with decompensated respiratory acidosis (pH below 7.30), hemodynamic instability requiring vasoactive drugs, or severe sepsis at admission.
  • Cognitive impairment, behavioral disorder or any circumstance preventing proper use of the device or compliance with study procedures.
  • Simultaneous participation in another interventional clinical trial, or readmission of a patient previously included in this study.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Egyetlen

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: EMILY

Automatic oxygen titration by EMILY.AI 24 hours a day from randomization to hospital discharge, targeting SpO2 91-97% (hypoxaemic) or 91-94% (hypercapnic).

Investigational smart oxygen valve with an embedded fuzzy-logic algorithm that adjusts oxygen flow every second from pulse-oximetry SpO2, heart rate and respiratory rate to keep SpO2 within a target range. Other names: EMILY.AI Smart Valve

Aktív összehasonlító: MANUAL

Usual care: fixed oxygen prescription adjusted by nursing staff, with vital signs checked every 8 hours. The EMILY.AI device is connected in fixed mode and only records data.

Usual care: oxygen flow set and adjusted by the ward nursing team according to standard practice. The EMILY.AI device stays connected in fixed mode, recording signals but not controlling delivery.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Percentage of time with SpO2 within the target range
Időkeret: From randomization to hospital discharge, up to 30 days.

Percentage of monitored time with SpO2, measured continuously by the device's pulse oximeter, within the target range for the type of respiratory failure (hypoxaemic 91-97%; hypercapnic 91-94%). Compared between the EMILY and MANUAL arms.

From randomization to hospital discharge, up to 30 days.

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Proportion of participants with SpO2 in range more than 95% of the time
Időkeret: From randomization to hospital discharge, up to 30 days.

Proportion of participants in each arm whose SpO2 stays within their target range for more than 95% of the monitored time.

From randomization to hospital discharge, up to 30 days.
Time with SpO2 below the target range
Időkeret: From randomization to hospital discharge, up to 30 days.

Percentage of monitored time with SpO2 below the target range for the type of respiratory failure (hypoxaemia).

From randomization to hospital discharge, up to 30 days.
Time with SpO2 above the target range
Időkeret: From randomization to hospital discharge, up to 30 days.

Percentage of monitored time with SpO2 above the target range while oxygen is being delivered (hyperoxaemia).

From randomization to hospital discharge, up to 30 days.
Nursing oxygen flow adjustments
Időkeret: From randomization to hospital discharge, up to 30 days.

Number of oxygen flow changes and oxygen interface changes made by nursing staff per shift (morning, afternoon, night).

From randomization to hospital discharge, up to 30 days.
Number of nursing vital sign measurements per shift
Időkeret: From randomization to hospital discharge, up to 30 days.

Total number of individual vital sign measurements taken by nursing staff per 8-hour shift, where each recording of SpO2, temperature, blood pressure, heart rate or respiratory rate counts as one measurement. For each participant, the counts are averaged across all shifts of the stay and reported as the mean number of measurements per shift.

From randomization to hospital discharge, up to 30 days.
Calls to the physician
Időkeret: From randomization to hospital discharge, up to 30 days.

Number of calls to the physician related to desaturation, oxygen flow changes or abnormal vital signs.

From randomization to hospital discharge, up to 30 days.
Total oxygen delivered
Időkeret: From randomization to hospital discharge, up to 30 days.

Total oxygen delivered (litres) during the hospital stay.

From randomization to hospital discharge, up to 30 days.
Mean oxygen flow
Időkeret: From randomization to hospital discharge, up to 30 days.

Mean oxygen flow (litres per minute) delivered during the hospital stay.

From randomization to hospital discharge, up to 30 days.
Length of hospital stay
Időkeret: From randomization to hospital discharge, up to 30 days.

Days from randomization to hospital discharge.

From randomization to hospital discharge, up to 30 days.
Escalation to a higher level of respiratory support
Időkeret: From randomization to hospital discharge, up to 30 days.

Proportion of participants requiring high-flow nasal cannula, non-invasive ventilation, or transfer to the Respiratory Intermediate Care Unit or ICU due to respiratory or hemodynamic deterioration.

From randomization to hospital discharge, up to 30 days.
Device alerts
Időkeret: From randomization to hospital discharge, up to 30 days.

Number of alerts generated by EMILY.AI related to oxygenation or vital signs per participant during the hospital stay.

From randomization to hospital discharge, up to 30 days.
Percentage of device alerts corresponding to a true clinical change
Időkeret: From randomization to hospital discharge, up to 30 days.

Percentage of EMILY.AI alerts confirmed by the clinical team as corresponding to a true clinical change.

From randomization to hospital discharge, up to 30 days.
Change in arterial partial pressure of oxygen (PaO2)
Időkeret: At randomization and at hospital discharge (up to 30 days).

Change in PaO2 (mmHg) measured by arterial blood gas analysis between randomization and hospital discharge.

At randomization and at hospital discharge (up to 30 days).
Change in arterial partial pressure of carbon dioxide (PaCO2)
Időkeret: At randomization and at hospital discharge (up to 30 days).

Change in PaCO2 (mmHg) measured by arterial blood gas analysis between randomization and hospital discharge.

At randomization and at hospital discharge (up to 30 days).
Change in arterial pH
Időkeret: At randomization and at hospital discharge (up to 30 days).

Change in arterial pH (pH units) measured by arterial blood gas analysis between randomization and hospital discharge.

At randomization and at hospital discharge (up to 30 days).
Change in dyspnoea measured with the modified Borg Dyspnoea Scale
Időkeret: At randomization and at hospital discharge (up to 30 days).

Change between randomization and hospital discharge in dyspnoea measured with the modified Borg Dyspnoea Scale, which ranges from 0 (no breathlessness at all) to 10 (maximal breathlessness). Higher scores mean a worse outcome.

At randomization and at hospital discharge (up to 30 days).
Satisfaction with oxygen therapy measured with a 5-point Likert scale
Időkeret: At hospital discharge (up to 30 days).

Participant-reported satisfaction with oxygen therapy at hospital discharge, measured with a single-item 5-point Likert scale ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores mean a better outcome.

At hospital discharge (up to 30 days).

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Intercurrent events
Időkeret: From randomization to hospital discharge, up to 30 days.

Number of participants with falls with clinical consequences, non-respiratory nosocomial infection, acute cardiovascular events, major bleeding, decompensation of non-respiratory comorbidity, social problems prolonging stay, or unplanned procedures.

From randomization to hospital discharge, up to 30 days.

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Nyomozók

  • Kutatásvezető: Sarah Beatrice Heili Frades, MD, PhD, MD, PhD, Hospital Universitario Fundación Jiménez Díaz

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2027. február 1.

Elsődleges befejezés (Becsült)

2027. december 1.

A tanulmány befejezése (Becsült)

2027. december 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. október 28.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 9.

Első közzététel (Tényleges)

2026. november 12.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 12.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 9.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Egyéb vizsgálati azonosító számok

  • FJD-EMILY-23-02-WARD
  • FJD-EMILY-23-02 (Egyéb azonosító: Aether Tech S.L.)

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

ELDÖNTETLEN

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel